What’s new in Breast Disease M. Whitney Parnell MD FACS Surgical Associates of Myrtle Beach Breast and General Surgery.

Slides:



Advertisements
Similar presentations
Progress Against Breast Cancer
Advertisements

Which of the following increases a women’s risk for Breast Cancer? A.Starting her menses at age 14 or older B.Breastfeeding C.Extremely dense breast tissue.
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Breast Cancer Screening What’s New to Know? The Issue of Breast Density Catherine Babcook MD Partner, Mountain Medical Physician Specialists Medical Director.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
Breast Density A patient guide.
BREAST CANCER UPDATE DETECTION TO DIAGNOSIS
Breast Histopathology : Mammography
Hereditary Factors in Breast Cancer
Hereditary breast and ovarian cancer Who should be screened and How? Symposium on Cancer Waterloo Inn October 31, 2007 Mala Bahl, MD, MSc.
Breast Cancer Risk and Risk Assessment Models
Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Breast Imaging Made Brief and Simple
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
Volumetric Breast Density understandbreastdensity.or g.
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
SUMAYYA EBRAHIM GYNAECOLOGIST PARKLANE CLINIC JOHANNESBURG
BREAST CANCER AWARENESS Sheraton Kuwait , Crystal Ballroom
Breast cancer screening Mammography is the most widely used screening modality, with solid evidence of benefit for women aged 40 to 74 years Clinical breast.
Dr Matt Hewitt Prophylactic Bilateral Salpingoophorectomy.
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
ACRIN Protocol 6666 ACRIN Protocol 6666 Screening Breast Ultrasound in High-Risk Women Made possible by grants from the Avon Foundation and National Cancer.
Atoosa Adibi MD. Department of Radiology Isfahan University Of Medical Sciences.
Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.
1 MAMMOGRAPHY RADIOGRAPHIC IMAGING OF THE BREAST Part 2 -Statistics A mammogram can find breast cancer when it is very small -- 2 to 3 years before you.
Breast cancer -most common -Second common ( Death ) new case ( 2003 ) diagnosed - Lifetime Risk 2.5 % ( 1-8 )
Vida! Educational Series – Promoting Good Health Welcome! - We will begin shortly If viewing by internet: for technical help: Please complete.
Breast Cancer Breast Cancer DR/FATMA AL-THOUBAITY ASSOCIATE PROFESSOR SURGICAL CONSULTANT.
IN THE NAME OF GOD BREAST DISEASE E.Naghshineh M.D.
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
Breast Cancer Screening Steven Stanten MD Rupert Horoupian MD AltaBates Summit Medical Center Oakland, California.
Breast Cancer. Introduction  As old as 1600 BC  Emerges from inner lining of milk ducts  Or the lobules that supply milk  Types:  DCIS  LCIS.
Personal Risk Factors Gender being a woman is the main risk factor for developing breast cancer (100 times more common in women) Age occurrence increase.
In The Name of God BREAST IMAGING N. Ahmadinejad Medical Imaging Center TUMS.
BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
MAMMOGRAPHY Denise Tomek Director of Diagnostic Imaging.
Breast Cancer Screening. Introduction Breast cancer is a fatal disease at advanced stages; however, it can be controlled through prevention and early.
Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.
Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.
Breast Density: Black, White and Shades of Gray Jen Rusiecki, MD VA Pittsburgh Health System Women’s Health Fellow AMWA Hot Topic 2016.
“Beyond Mammography” Len Saputo, MD For a free download of this go to this URL:
Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in
By: Anthony, Sophia, Jessica, Terrance, and Sierra.
Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.
Dr. Julia Flukinger Breast Radiologist, Director Breast MRI, Advanced Radiology May 21, 2106.
Breast Cancer in Young Women by Kim Wooden 1. Facts While the majority of women who develop breast cancer are postmenopausal, younger women are more likely.
The Elliott Breast Center * Baton Rouge, LA *
Hereditary Cancer Predisposition: Updates in Genetic Testing
TMIST A Breast Cancer Screening Trial
Screening for Ovarian Cancer
Cancer Screening Guidelines
Breast Cancer Updates Risks, Genetics, DCIS
Ari Brooks, MD Cancer Surgeon, Big Data End User
Mammograms and Breast Exams: When to start /stop mammograms
Breast Cancer Screening/Imaging
Demystifying Cancer Genetics
Breast cancer screening recommendations
Cancer screening PROF .MAZIN AL-HAWAZ.
Breast Screening and Risk Assessment
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Who in the room would offer BRCA1/2 testing to this patient Who in the room would offer BRCA1/2 testing to this patient? How might the medical management.
Breast Imaging Ravi Adhikary, MD.
Breast Cancer Guideline Update – Sharp Focus on Who is at Risk
Diagnosis of breast cancer in women age 40 and younger: Delays in diagnosis result from underuse of genetic testing and breast imaging 95% of patients.
INTEGRATED CARE MANAGEMENT AND QUALITY IMPROVEMENT
INTEGRATED CARE MANAGEMENT AND QUALITY IMPROVEMENT
imaging modalities for Breast screening
Presentation transcript:

What’s new in Breast Disease M. Whitney Parnell MD FACS Surgical Associates of Myrtle Beach Breast and General Surgery

 Dense Breasts  ABUS  3-D Mammography  BRCA1 BRCA2 and beyond  Prophylactic Surgery  Cancer Sub-typing (oncotype DX/Mammoprint) Hot topics

What does it mean to say dense breasts? Who has dense breasts? Are women with dense breasts at increased risk of developing cancer? What should we do differently? Legislation Dense Breasts

Breast Anatomy  Fat and glandular tissue  More glandular tissue=denser breast  Denser the breasts the whiter the mammogram  Mammogram may miss up to 40% of cancers in dense breasts

Dense Breasts  Age  Hormone levels  Genetics  Age at first pregnancy  #of pregnancies  HRT

Mammograpy’s dirty little secret  Up to 40% of cancer can be missed on standard mammography in dense breasts !

 Type 1—mostly fatty replaced  Type 2 Average breast tissue 25-50%  Type 3 Heterogenously dense 50-75%  Type 4 Extremely dense >75% dense tissue Dense breast Classifications

Dense Breast Classifications

Why Mammography?  Inexpensive  Safe (low radiation)  Accessible  Sensitive and Specific  Effective in reducing mortality from Breast Cancer  Since 1990’s there has been a decrease in mortality from breast cancer 2.2%/year due to screening mammography

 Most frequent dx non-skin cancer in Women  226,870 new cases/yr in US  63,000 new cases of DCIS  40,000 women die annually of breast cancer  Second leading cause of cancer death in women Breast Cancer Stats

Breast Cancer Risk Factors  Early menarche  Late Menopause  Nulliparous  HRT  Post-menopausal obesity  ETOH  Breast Density

 Dense breast are an independent risk cancer for cancer development  Mult retrospective studies show the odds ratios for developing breast cancer in the least dense compared with the densest breast ranges from (ave 4.0)  Harvey et al. Radiology 2004 Dense breasts=more Cancer?

 Breast cancer is a progressive disease and early detection offers women an opportunity to halt the natural evolution of the cancer, increases her treatment options, and ultimately saves lives. Early Detection

 Mammogram is still the gold standard for screening and it is an invaluable tool—  Assessing interval change  Architectural distortions  Calcifications (i.e. DCIS—stage 0) Why get a mammogram if I have dense breasts?

 Breast Ultrasound  MRI  Digital breast tomosynthesis Other Imaging Modalities

 Safe—no radiation  Technologic advancements have improved resolution  Breast density is a non-issue  Easy to perform  Well tolerated by patient  Invaluable asset to mammography Ultrasound

 High risk women with dense breasts  Improved cancer detection 13-28%  Most cancers were early stage invasive node negative cancer  Kolbe et al Radiology 2002  ACRIN 6666; JAMA 2008 Improved Cancer Detection

 Connecticut was first 2009—Public Act  "If your mammogram demonstrates that you have dense breast tissue, which could hide small abnormalities, you might benefit from supplementary screening tests, which can include a breast ultrasound screening or a breast MRI examination, or both, depending on your individual risk factors. A report of your mammography results, which contains information about your breast density, has been sent to your physician's office and you should contact your physician if you have any questions or concerns about this report. Legislation

 First year experience with the new law requiring all women with dense breasts to be screened with u/s along with the mammogra  935 women; 5% had suspicious u/s—bx  PPV was 6.5%  Overall cancer detection rate 3.2/1000  Hooley et al. Screening US in patients with Mammographically dense breasts: Initial Experience with Connecticut Public Act  Radiology; :59-69 Connecticut

South Carolina  Introduce bill Feb 2013  Currently in the House Committee on Labor Commerce and Industry  Sponsored by Senator Joel Lourie

 Staffing/Time intensive with low reimbursement  Technician dependent  ACR/ACS lack guidelines  Adding u/s to mammography increases the false positive rate 4X— ACRIN 6666: Jama 2008 Breast Ultrasound

 Automated Breast Ultrasound Screening  3mins per breast (19mins with u/s tech)  Full exam time 15 mins  Gives complete 3-D volumetric imaging of the breast  Approved in Sept 2012 “explicitly for breast cancer screening for asymptomatic women with dense breast tissue.”  97% sensitive when used with mammograpy ABUS

 ACS guidelines Recommended for high risk individuals annually with mammography  Known BRCA 1 or 2 mutations  First degree family member with genetic mutation  >20% lifetime risk based on Risk analysis models  Chest wall radiation ages  Li-Fraumeni, Cowden and Bannayan-Riely Ruvalcaba syndromes and first degree relatives Breast MRI

 Expensive  Requires contrast agent (baseline creatinine)  Uncomfortable (prone position)  Lacks insurance mandate  Lacks specificity  Time in the magnet Breast MRI

 Originally approved as add-on only  FDA 2013-approved for use without standard 2-D mammography  Provides images of the breast in “slices” from many different angles  Not always covered by insurance  Machines cost 2x as much 3-D Mammography

 Higher cancer detection rate 4.1 vs 2.9/1000  Less call backs 91 vs 107/1000  Higher bx rate 19.3 vs 18.1  Higher radiation dose (both within safe limits)  Overseas use since 2008—restrict it to patients with breast problems  JAMA. 2014;311(24): D Mammography

 BRCA1 and BRCA 2 are human genes that produce tumor suppressor proteins  Help repair damaged DNA  With mutations of these genes—damaged DNA is not repaired properly  Responsible for 25% of genetic breast cancer  5-10% of all breast cancer  15% of ovarian cancer Genetics

BRCA1  55-65% will develop breast cancer in their lifetime  40% lifetime risk of ovarian cancer  Fallopian tube and peritoneal cancer  Prostate cancer  Pancreatic cancer BRCA2  45% will develop breast cancer in their lifetime  12% lifetime risk of ovarian caner  Linked with male breast cancer  Prostate cancer  Pancreatic cancer

Who should get tested?  Breast cancer before 50  Cancer in both breasts  Breast and ovarian cancer  Personal or family hx of Male breast cancer  Triple negative breast cancer before age 60  Ashkenazi Jewish heritage and family hx of breast or ovarian cancer  Ovarian cancer before 50

3 rules  Multiple –combination of cancers in the same side of the family  Young --<50  Rare —male breast; triple neg; colorectal or endometrial cancer with abnormal MSI/IHC;

 Identifies elevated risk of 8 cancers by analyzing multiple clincally actionable genes  Retrospective analysis of patients ( )  6.9% of patients appropriate for HBOC testing also meet Lynch criteria  30% of patients appropriate for Lynch testing also meet HBOC Expanded panel testing

 Previvor - "Cancer previvors" are individuals who are survivors of a predisposition to cancer but who haven’t had the disease. This group includes people who carry a hereditary mutation, a family history of cancer, or some other predisposing factor.  Unaffected carrier Previvor

 Increased awareness  Increased inquiries into testing  Better lay understanding of genetic testing  Prophylactic Mastectomy Angelina Jolie Effect

 Risk reduction of 90+ %  Still need to consider prophylactic oophorectomy  Nipple sparing techniques (1% less risk reduction) Prophylactic Mastectomy

Molecular profiling  Oncotype Dx  Mammoprint

 Genomic test of the activity of a group of genes  How cancer may respond to treatment  Early stage ER+ breast cancer recurrence and ?benefit from chemo  DCIS—recurrence and or risk of new invasive cancer developing and ?benefit from XRT OncotypeDX

Summary  Dense breasts Birads 3 and 4 benefit from annnual screening ultrasound  Consider genetic testing for multiple/ young/rare  Nipple sparing prophylatic mastectomy option  Cancer molecular profiling or subtyping expanding—targeted therapy

Questions? Questions